Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Focusing on Prevention						Print
											PAGE 4 of 5
					**‹**View Table of Contents					Related Pages
										Return to TB Elimination Champions
**SheAnne Allen**
SheAnne Allen
SheAnne Allen has a relentless dedication and passion to TB prevention. She has an expansive vision on how to end TB in Washington State. In 2015, SheAnne not only led the Washington State Department of Health TB Program, but her vision allowed the program to be truly innovative.
SheAnne was instrumental in the innovative application and implementation of TB Project ECHO® in Washington. Washington’s TB ECHO® is the first of its kind. It focuses on latent TB infection treatment by partnering with private providers and community health centers to reduce the number of people at risk of developing TB disease later in life. Expanding latent TB infection treatment to primary care is critical. It is even more critical in areas of Washington with limited public health resources and respiratory/infectious disease specialists.
SheAnne’s contributions were essential to an effective contact investigation of over 1200 students and faculty in a large public school. The contact investigation was done in four days. Under her leadership and guidance as the State TB Controller, over 1200 individuals were evaluated for TB infection. Fifty of those people had a chest x-ray done because they had symptoms suggestive of active TB or a positive TB test. Those who had latent TB infection completed treatment. SheAnne’s efforts substantially reduced their risk of developing active TB disease.
SheAnne continues work toward making latent TB infection a notifiable condition in the State of Washington. By making latent TB infection a notifiable condition, primary care providers would be required to notify the state health department of any individuals testing positive for TB infection. This will allow for tailored communication and recommendations on treatment options. By spearheading this movement, SheAnne is actively working towards changing state policy in the effort to reduce the number of active TB cases through prevention.

**Jennifer Flood**
Dr. Jennifer Flood is the Chief of the TB Control Branch
Dr. Jennifer Flood is the Chief of the TB Control Branch, California Department of Public Health (CDPH). She is a driving force for innovation and collaboration in a state where the opportunities and challenges for TB elimination are ever present. She embodies the skills, commitment, and courageous leadership needed in a jurisdiction where 22% of the nation’s TB cases reside.
One of Dr. Flood’s greatest contributions to TB elimination is her leadership in both building partnerships and as a champion for TB prevention. Under Dr. Flood’s guidance and leadership, in May 2015, the California TB Elimination Task Force convened to explore how best to address the opportunity to eliminate TB in California by 2040. This Task Force was a collaboration of CDPH, the University of California, San Francisco, and the California TB Controllers Association (CTCA), with funding from the California HealthCare Foundation. Through thoughtful analysis of the evidence base, the Task Force identified six key groups of interventions needed to reach TB elimination in California. In December 2015, Dr. Flood led the effort to assemble a diverse group of 50 stakeholders to share their perspectives on the Task Force recommendations. They group would also to inform the development of a statewide TB elimination action plan. The meeting was an unprecedented collaboration of key representatives from TB control and other public health programs, managed care, community-based organizations, border health, corrections, and implementation partners such as CITC.
As a cornerstone in the elimination plan, Dr. Flood has placed TB prevention front and center through focused targeting of latent TB infection. In 2015, she led the CDPH/CTCA creation of a “TB Risk Assessment Tool” to help clinicians identify adults for latent TB infection testing who are at high-risk for TB exposure or progression to TB disease. Widespread implementation of this tool represents just one piece in the overall California TB elimination plan, but its utility as an adaptable tool has already found support across the country.
Dr. Flood is a passionate, committed, innovative, and inspirational leader who has greatly contributed to TB control in California for over a decade. With her vision and stewardship, California is moving closer to TB elimination.

									Supporting TB ControlBuilding PartnershipsExpanding Testing and Treatment**›****Focusing on Prevention**Maximizing Resources
							
					
							Last Reviewed:  March 24, 2016						Source: 	Division of Tuberculosis Elimination
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue